LXRX Lexicon Pharmaceuticals Inc.

5.58
-0.08  -1%
Previous Close 5.66
Open 5.65
Price To Book -22.32
Market Cap 592997353
Shares 106,271,927
Volume 645,697
Short Ratio
Av. Daily Volume 923,902

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
CRL issued March 22, 2019.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 data due 4Q 2019.
Sotagliflozin
Type 2 Diabetes
Phase 1b trial to be initiated 1Q 2019 with top-line data due 2H 2019.
LX9211
Neuropathic pain
Phase 2a initiation of dosing announced March 15, 2019. Top-line data due 2020.
Telotristat ethyl - TELE-ABC
Biliary tract cancer (BTC)

Latest News

  1. Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop?
  2. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
  3. CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  4. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm
  5. FINAL DEADLINE - (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019
  6. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN
  7. CLASS ACTION UPDATE for LXRX, UXIN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  8. AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
  9. Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
  10. Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action
  11. Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX)
  12. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX
  13. Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
  14. AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
  15. What's Next for Lexicon Pharmaceuticals?
  16. This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment
  17. Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today
  18. FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes